Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL) [SIN16856P]

Active ingredients: COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)

View product's general information
Last updated 24 April 2026

Product Info

COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (SINGLE-DOSE VIAL)

[SIN16856P]

Product information

Active Ingredient and Strength

FAMTOZINAMERAN - 15 ΜCG/DOSE
TOZINAMERAN - 15 ΜCG/DOSE

Dosage Form

INJECTION

Manufacturer and Country

PFIZER MANUFACTURING BELGIUM NV - BELGIUM
SANOFI-AVENTIS DEUTSCHLAND GMBH - GERMANY
MIBE GMBH ARZNEIMITTEL - GERMANY
ALLERGOPHARMA GMBH & CO. KG - GERMANY
PATHEON ITALIA S.P.A - ITALY
BIONTECH MANUFACTURING MARBURG GMBH - GERMANY

Registration Number

SIN16856P

Licence Holder

BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

J07BN01

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

4.1 Therapeutic indications

COMIRNATY (Bivalent) (For 12 Years of Age and Older) (Vials with Grey Cap) is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 virus, in individuals 12 years of age and older.

The use of this vaccine should be in accordance with official recommendations.

Dosing

4.2 Posology and method of administration

Posology

Booster dose in individuals 12 years of age and older

A booster dose of COMIRNATY (Bivalent) (For 12 Years of Age and Older) (Vials with Grey Cap) may be administered intramuscularly after completing the primary series of COMIRNATY or after a previous booster dose of COMIRNATY or COMIRNATY (Bivalent) (For 12 Years of Age and Older) (Vials with Grey Cap).

For further information on efficacy, see section 5.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.

Paediatric population
The safety and efficacy of COMIRNATY (Bivalent) in children aged less than 12 years has not yet been established.

Elderly population
No dosage adjustment is required in elderly individuals ≥65 years of age. The safety of a booster dose of COMIRNATY in individuals 65 years of age and older is based on safety data in 12 booster dose recipients 65 through 85 years of age in Study 2, 306 booster dose recipients 18 through 55 years of age in Study 2, and 1,175 booster dose recipients 65 years of age and older in Study 4. The safety of COMIRNATY (Bivalent) as a second booster in individuals 65 years of age and older is based on safety data in 159 booster dose recipients 65 years of age and older and 35 booster dose recipients 75 years of age and older in C4591044 (Study 5). The effectiveness of a booster dose of COMIRNATY in individuals 65 years of age and older is based on effectiveness data in 306 booster dose recipients 18 through 55 years of age in Study 2, and an efficacy analysis from participants 16 years of age and older in 9,945 participants in Study 4.

Method of administration

COMIRNATY (Bivalent) should be administered intramuscularly (see section 6.6 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). The preferred site is the deltoid muscle of the upper arm.

Do not inject the vaccine intravascularly, subcutaneously or intradermally.

Single dose vials
Single dose vials of COMIRNATY (Bivalent) (For 12 Years of Age and Older) (Vials with Grey Cap) contain 1 dose of 0.3 mL of vaccine.

  • Withdraw a single 0.3 mL dose of COMIRNATY (Bivalent) (For 12 Years of Age and Older) (Vials with Grey Cap).

  • Discard vial and any excess volume.

  • Do not pool excess vaccine from multiple vials.

Multidose vials
Multidose vials of COMIRNATY (Bivalent) (For 12 Years of Age and Older) (Vials with Grey Cap) contain 6 doses of 0.3 mL of vaccine.

Low dead-volume syringes and/or needles can be used to extract 6 doses from a single vial. The low dead-volume syringe and needle combination should have a dead volume of no more than 35 microlitres. If standard syringes and needles are used, there may not be sufficient volume to extract a sixth dose from a single vial. Irrespective of the type of syringe and needle:

  • Each dose must contain 0.3 mL of vaccine.

  • If the amount of vaccine remaining in the vial cannot provide a full dose of 0.3 mL, discard the vial and any excess volume.

  • Do not pool excess vaccine from multiple vials.

The vaccine should not be mixed in the same syringe with any other vaccines or medicinal products.

For precautions to be taken before administering the vaccine, see section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.

For instructions regarding thawing, handling, dose preparation of vaccine before administration, and disposal of the vaccine, see section 6.6 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.

Contraindications

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.